North Boston News

WASHINGTON, DC – The consequences of drug shortages are particularly dire, affecting both adult and pediatric patients. Many community cancer centers are now unable to provide necessary treatments due to the scarcity of cancer drugs and large academic cancer centers have reported having less than a two-week supply of these vital medications on hand. 

To call attention to these shortages, Rep. Seth Moulton (MA-06) joined Rep. Ami Bera (CA-06) and 60+ Members in a bipartisan letter to the U.S. Department of Health and Human Services Secretary Xavier Becerra and U.S. Food and Drug Administration Commissioner Robert Califf expressing concern about the detrimental impact of drug shortages on individuals battling cancer. 

“Patients, physicians, and pharmacists are often the last to know when an essential drug will no longer be available, yet, are affected by these shortages the most. We strive to ensure patients, physicians, and pharmacists never have to experience shortages of essential medications, but when shortages do occur it is vital that these individuals are made aware as quickly as possible so that they can better prepare,” wrote the lawmakers. “We appreciate the actions FDA has already taken to address the ongoing cancer drug shortage and encourage you to take all appropriate steps to protect this vulnerable population. We stand ready to assist you in any way possible.”

Out of the 136 drugs the FDA reports are currently in shortage, 15 are oncology medications that are widely used in the treatment of common, treatable cancers, including lung, breast, ovarian, testicular, head and neck cancer, endometrial cancer, and many types of childhood cancers. 

You can read the letter in full here.

Original source can be found here.